SG Americas Securities LLC increased its stake in CEL-SCI Co. (NYSEAMERICAN:CVM) by 424.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,170 shares of the company’s stock after acquiring an additional 47,888 shares during the quarter. SG Americas Securities LLC owned about 0.16% of CEL-SCI worth $883,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of CVM. Renaissance Technologies LLC acquired a new position in CEL-SCI in the fourth quarter valued at approximately $408,000. UBS Group AG lifted its stake in CEL-SCI by 215.7% in the fourth quarter. UBS Group AG now owns 35,301 shares of the company’s stock valued at $323,000 after buying an additional 24,118 shares during the period. Goldman Sachs Group Inc. lifted its stake in CEL-SCI by 31.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 17,330 shares of the company’s stock valued at $159,000 after buying an additional 4,156 shares during the period. Bank of New York Mellon Corp lifted its stake in CEL-SCI by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 96,961 shares of the company’s stock valued at $887,000 after buying an additional 2,817 shares during the period. Finally, Bank of America Corp DE lifted its stake in CEL-SCI by 70.6% in the fourth quarter. Bank of America Corp DE now owns 22,531 shares of the company’s stock valued at $206,000 after buying an additional 9,322 shares during the period.
Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $23.00 price objective (up previously from $18.00) on shares of CEL-SCI in a report on Thursday, May 14th. BidaskClub downgraded CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday.
CEL-SCI (NYSEAMERICAN:CVM) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.10 million.
CEL-SCI Company Profile
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Read More: Average Daily Trade Volume – ADTV
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.